Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells.

Humans Histone Deacetylase Inhibitors / pharmacology Cell Line, Tumor MicroRNAs Cell Proliferation Antineoplastic Agents / pharmacology Hydroxamic Acids / pharmacology Apoptosis Pyridines / pharmacology Histone Deacetylase 1 Neoplasms
Apoptosis Cancer HDAC inhibitors Histone acetylation Proliferation miRNAs

Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
05 Feb 2023
Historique:
received: 19 09 2022
revised: 07 12 2022
accepted: 12 12 2022
pubmed: 23 12 2022
medline: 18 1 2023
entrez: 22 12 2022
Statut: ppublish

Résumé

After over 30 years of research, the development of HDAC inhibitors led to five FDA/Chinese FDA-approved drugs and many others under clinical or preclinical investigation to treat cancer and non-cancer diseases. Herein, based on our recent development of pyridine-based isomers as HDAC inhibitors, we report a series of novel 5-acylamino-2-pyridylacrylic- and -picolinic hydroxamates and 2'-aminoanilides 5-8 as anticancer agents. The hydroxamate 5d proved to be quite HDAC3/6-selective exhibiting IC

Identifiants

DOI: 10.1016/j.ejmech.2022.115022 PMID: 36549114
pubmed: 36549114
pii: S0223-5234(22)00924-2
doi: 10.1016/j.ejmech.2022.115022
pii:
doi:

Substances chimiques

Histone Deacetylase Inhibitors 0
MicroRNAs 0
Antineoplastic Agents 0
Hydroxamic Acids 0
Pyridines 0
Histone Deacetylase 1 EC 3.5.1.98

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115022

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Elisabetta Di Bello (E)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.

Veronica Sian (V)

Department of Precision Medicine, "Luigi Vanvitelli" University of Campania, Via L. De Crecchio 7, 80138, Naples, Italy.

Giulio Bontempi (G)

Department of Molecular Medicine, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy; Gene Expression Laboratory, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Clemens Zwergel (C)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.

Rossella Fioravanti (R)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.

Beatrice Noce (B)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.

Carola Castiello (C)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.

Stefano Tomassi (S)

Department of Pharmacy, University of Naples "Federico II", Via D. Montesano 49, 80131, Naples, Italy.

Davide Corinti (D)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.

Daniela Passeri (D)

TES Pharma S.r.l., Via P. Togliatti 20, Corciano, 06073, Perugia, Italy.

Roberto Pellicciari (R)

TES Pharma S.r.l., Via P. Togliatti 20, Corciano, 06073, Perugia, Italy.

Ciro Mercurio (C)

IFOM ETS, The AIRC Institute of Molecular Oncology, Via Adamello 16, 20139, Milan, Italy.

Mario Varasi (M)

IFOM ETS, The AIRC Institute of Molecular Oncology, Via Adamello 16, 20139, Milan, Italy.

Lucia Altucci (L)

Department of Precision Medicine, "Luigi Vanvitelli" University of Campania, Via L. De Crecchio 7, 80138, Naples, Italy.

Marco Tripodi (M)

Department of Molecular Medicine, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy; Gene Expression Laboratory, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Raffaele Strippoli (R)

Department of Molecular Medicine, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy; Gene Expression Laboratory, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Via Portuense, 292, 00149, Rome, Italy. Electronic address: raffaele.strippoli@uniroma1.it.

Angela Nebbioso (A)

Department of Precision Medicine, "Luigi Vanvitelli" University of Campania, Via L. De Crecchio 7, 80138, Naples, Italy. Electronic address: angela.nebbioso@unicampania.it.

Sergio Valente (S)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy. Electronic address: sergio.valente@uniroma1.it.

Antonello Mai (A)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy; Pasteur Institute, Cenci-Bolognetti Foundation, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Novel pyridine-containing histone deacetylase...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de désacétylase d'histone › Novel pyridine-containing histone deacetylase...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Novel pyridine-containing histone deacetylase...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › microARN › Novel pyridine-containing histone deacetylase...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Novel pyridine-containing histone deacetylase...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Novel pyridine-containing histone deacetylase...
questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Hydroxyacides › Acides hydroxamiques › Novel pyridine-containing histone deacetylase...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Novel pyridine-containing histone deacetylase...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Novel pyridine-containing histone deacetylase...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Complexes multienzymatiques › Histone Deacetylase 1 › Novel pyridine-containing histone deacetylase...
questionsmedicales.fr › Tumeurs › Novel pyridine-containing histone deacetylase...